11 / 31
Overall Survival
CALGB
(n = 526)
FIRE-3
(n = 342)
PEAK
(n = 170)
Total
(fixed)
Total
(random)
HR (95% CI)
0.90
(0.70−1.10)
0.70
(0.53−0.92)
0.76
(0.53−1.11)
0.80
(0.67−0.93)
0.79
(0.67−0.94)
−0.105
−0.357
−0.462
0.1153
0.1407
0.2453
52.8
35.5
17.3
100
logHR
logSE
Weight
Favours anti-EGFR + CTx
0.1
1
Favours bevacizumab + CTx
10
Heterogeneity: Chi
2
= 2.87, df = 2, (P = 0.24), I
2
= 30%, Tau
2
= 0.01
WT
RAS
Heinemann V, et al. Ann Oncol 2015.